Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of EBT Margin data on record, last reported at 236.98% in Q3 2025.

  • For Q3 2025, EBT Margin rose 2113.0% year-over-year to 236.98%; the TTM value through Sep 2025 reached 12.09%, up 80678.0%, while the annual FY2024 figure was 92.74%, N/A changed from the prior year.
  • EBT Margin reached 236.98% in Q3 2025 per GLUE's latest filing, down from 47.84% in the prior quarter.
  • Across five years, EBT Margin topped out at 56.17% in Q1 2025 and bottomed at 2996.71% in Q1 2024.